Biodexa Pharmaceuticals (BDRX) Cash from Restructuring (2014 - 2015)
Biodexa Pharmaceuticals (BDRX) posted Cash from Restructuring of $3.9 million for Q4 2015, up 1321.62% sequentially from $272517.3 in Q4 2014, and up 1321.62% YoY from $272517.3 in Q4 2014.
Biodexa Pharmaceuticals (BDRX) Cash from Restructuring (2014 - 2015) Analysis & Trends
Biodexa Pharmaceuticals has reported Cash from Restructuring for 2 years, with the latest figure at $3.9 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - |
| 10 | Biodexa Pharmaceuticals | 63,673.51 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 3.87 Mn |
| Dec 31, 2014 | 272,517.33 |